Joseph J.  Wolk net worth and biography

Joseph Wolk Biography and Net Worth

Joseph J. Wolk (Joe) is the Executive Vice President and Chief Financial Officer for Johnson & Johnson. Joe serves as a member of company’s Executive Committee, playing a strategic role in the overall management of the organization and leading the development and execution of the business’ global long-term financial strategy. Additionally, as the financial steward of Johnson & Johnson, Joe’s scope of responsibilities includes driving competitive and profitable growth, generating sustainable cash flow, allocating capital to maximize value creation and managing risk across the entire enterprise.

Joe leads the worldwide Finance and Global Services organizations, which includes approximately 9,000 colleagues around the globe. He has been with Johnson & Johnson for 24 years, assuming the role of Chief Financial Officer in 2018.

Prior to assuming his current responsibilities, Joe was the Vice President of Investor Relations for Johnson & Johnson. In this role, he developed a winning strategy for building strong relationships with the investment community and disseminating Johnson & Johnson’s value creation narrative to all external financial stakeholders. During Joe’s tenure in this role, the Investor Relations function was regularly recognized by Institutional Investor as one of the best teams in the industry.

Prior to Investor Relations, Joe held a variety of senior leadership roles in several sectors and functions across the company, where he achieved superior results. He served as Vice President of Finance for the Pharmaceuticals Group, Vice President of Finance for the Medical Devices Global Supply Chain and Chief Financial Officer of the North America Pharmaceuticals Group.

Joe is an accomplished, Credo-based leader; passionate about talent development, driving innovation, and community service. He is the executive sponsor of Johnson & Johnson’s Impact Venture Fund, an “impact investment” fund that provides funding to entrepreneurs and their start-up companies or social enterprises to address healthcare challenges impacting people around the world. He is also the executive sponsor of the Veterans Leadership Council and a champion of the Finance Leadership Development Program. Additionally, he is a member of the Stanford Medicine Board of Fellows, the CNBC Global CFO Council and the Wall Street Journal CFO Network.

Joe holds a Bachelor of Science degree in Finance from St. Joseph’s University, where he serves on the University’s Board of Trustees and was recently inducted into the University’s Haub School of Business Hall of Fame for his excellence in business management. He earned his Juris Doctor degree from Temple University School of Law and is also a Certified Public Accountant (CPA).

What is Joseph J. Wolk's net worth?

The estimated net worth of Joseph J. Wolk is at least $5.22 million as of December 13th, 2022. Mr. Wolk owns 35,812 shares of Johnson & Johnson stock worth more than $5,216,018 as of June 19th. This net worth evaluation does not reflect any other assets that Mr. Wolk may own. Learn More about Joseph J. Wolk's net worth.

How do I contact Joseph J. Wolk?

The corporate mailing address for Mr. Wolk and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400 and via email at [email protected]. Learn More on Joseph J. Wolk's contact information.

Has Joseph J. Wolk been buying or selling shares of Johnson & Johnson?

Joseph J. Wolk has not been actively trading shares of Johnson & Johnson within the last three months. Most recently, Joseph J. Wolk sold 14,781 shares of the business's stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a transaction totalling $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares of the company's stock, valued at $6,431,835.20. Learn More on Joseph J. Wolk's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Director ), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (Insider), Jennifer Taubert (EVP), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, insiders at the sold shares 4 times. They sold a total of 97,820 shares worth more than $15,312,567.44. The most recent insider tranaction occured on February, 16th when Major Shareholder & Johnson Johnson sold 3,725 shares worth more than $96,142.25. Insiders at Johnson & Johnson own 0.2% of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 2/16/2024.

Joseph J. Wolk Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2022Sell14,781$179.60$2,654,667.6035,812View SEC Filing Icon  
See Full Table

Joseph J. Wolk Buying and Selling Activity at Johnson & Johnson

This chart shows Joseph J Wolk's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $145.65
Low: $145.27
High: $146.39

50 Day Range

MA: $148.13
Low: $144.40
High: $154.68

2 Week Range

Now: $145.65
Low: $143.13
High: $175.97


6,156,572 shs

Average Volume

6,944,967 shs

Market Capitalization

$350.53 billion

P/E Ratio


Dividend Yield